Wasserman Zelda R
Incyte Corporation, Experimental Station, Route 141 and Henry Clay Road, Wilmington, Delaware 19880, USA
Chem Biol. 2005 Feb;12(2):143-4. doi: 10.1016/j.chembiol.2005.01.008.
The paradigm for matrix metalloprotease inhibition combines active site tailoring and catalytic zinc ligation. But, selectivity has been difficult. Now, Engel et al. present novel compounds, completely selective for MMP-13, with a unique binding mode.
